French government acts to shorten reimbursement delays
This article was originally published in Clinica
Moves are afoot in France to speed up the time that it takes for innovative products to be accepted for reimbursement.
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.
Suppliers to the UK’s National Health Service from outside the EU could save up to 12% in costs for some equipment during COVID-19 emergency measures as the UK tries to increase supplies